Services & Products
Resources
News & Events
- News
- Events
Company

Services & Products
Resources
News & Events
- News
- Events
Company

Services & Products
- Genetic Toxicology
  - ToxTracker Suite
  - Other assays
- Developmental Toxicology
  - ReproTracker
- Mechanistic Toxicology
  - ToxProfiler
- Cytotoxicity
  - Clonogenic survival
  - Alamar Blue
Resources
News & Events
- News
- Events
Company

Author: ivo

All
Blog
Grants
News
Newsletter
Press Release
Publications
Uncategorized
Webinar

ivo

Eurotox announcement to visit us

Eurotox announcement to visit us newsletter...

Newsletter

September 1, 2016

Events

Visit us at our upcomming events.

SOT Annual Meeting and ToxExpo
19-03-2023 to 23-03-2023
2023 Genetic Toxicology Annual Meeting
03-05-2023 to 05-05-2023
51st congress of the European Environmental Mutagenesis and Genomics Society (EEMGS)
15-05-2023 to 18-05-2023
63rd Annual Meeting, Society for birth defects research and prevention mission
24-06-2023 to 28-06-2023
United Kingdom Environmental Mutagen Society Meeting (UKEMS)
02-07-2023 to 05-07-2023
12th World Congress on Alternatives and Animal Use in the Life Sciences
27-08-2023 to 31-08-2023
Environmental Mutagenesis & Genomics Society 54th Annual Meeting
09-09-2023 to 13-09-2023
57th Congress of the European Toxicologists and European Societies of Toxicology (EUROTOX)
10-09-2023 to 13-09-2023
51st annual meeting of the European Teratology Society
17-09-2023 to 20-09-2023
ACT 44th Annual Meeting
12-11-2023 to 15-11-2023

Sign up for our newsletter

Email Address

Very exciting new collaboration with IIVS. https://t.co/A1ZTdCnrTE
Less than 2 weeks to register for the webinar on DNA Repair-Profiler, a new in vitro assay for DNA repair and genot… https://t.co/0rPcrt8CNz
Join our webinar on DNA Repair-Profiler, a new in vitro assay for DNA repair and genotoxic mode of action assessmen… https://t.co/EDnmdYGSTF

About Us

Toxys is a Dutch biotech company that provides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development.